MLLT3 Regulates Melanoma Stemness and Progression by Inhibiting HMGB1 Nuclear Entry and MAGEA1 M 5 C Modification
Advanced Science · 2025-03 · 12 (10)
DOI: 10.1002/advs.202408529 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 24.12.2024. Verfasst von Yaling Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical and Health Engineering, Shen Zhen Institutes of Advanced Technology, Chinese Academy of Science, Shenzhen, Guangdong, 518055,…. Hauptthemen laut MEDLINE: Melanoma, Neoplastic Stem Cells, Antigens, Neoplasm, HMGB1 Protein. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shenzhen Key Medical Discipline Construction Fund, Peking University Shenzhen Hospital Scientific Research Fund.
Abstract (Originalsprache)
Melanoma stem cells are a kind of cells with self‐renewal and multi‐directional differentiation potential. They are one of the key factors in the occurrence, development and metastasis of melanoma. This study demonstrates that MLLT3 is a transcription factor that regulates the stemness and progression of melanoma. MLLT3 interacted with HMGB1 to inhibit its entry into the nucleus, MLLT3 interacted with YBX1 to inhibit its reading of m 5 C of MAGEA1 , thereby inhibiting the mRNA stability of MAGEA1 , and directly transcribed P53 to inhibit the stemness, proliferation and metastasis of melanoma cells. This study further explored the potential mechanism of the interaction between miR‐542‐3p/miR‐3922‐3p and MLLT3 . Furthermore, the scRNA‐seq of melanoma cells with MLLT3 knock‐out resulted in important changes in cell subsets, activating the TP53 and MAPK pathways and transforming into stem cells. The results indicate that the transcription factor MLLT3 is a suppressor gene that regulates the stemness and progression of melanoma, and is expected to become a target for melanoma therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biomedical and Health Engineering, Shen Zhen Institutes of Advanced Technology, Chinese Academy of Science, Shenzhen, Guangdong, 518055, China.
- Department of Dermatology, Institute of Dermatology, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong, 518036, China.
- Department of Dermatology, the First Hospital of China Medical University, Shenyang, Liaoning, 110001, China.
- Department of Otorhinolaryngology, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, 361000, China.
ORCID-Profile: Yaling Li
Förderung
- National Natural Science Foundation of China
- Shenzhen Key Medical Discipline Construction Fund
- Peking University Shenzhen Hospital Scientific Research Fund
- Sanming Project of Medicine in Shenzen Municipality
Zitieren
APA
Li, Y., Liu, H., Li, J., Fu, C., Jiang, B., Chen, B., Zou, Y., Yu, B., & Song, B. (2025). MLLT3 Regulates Melanoma Stemness and Progression by Inhibiting HMGB1 Nuclear Entry and MAGEA1 M 5 C Modification. Advanced Science, 12(10). https://doi.org/10.1002/advs.202408529
Vancouver
Li Y, Liu H, Li J, Fu C, Jiang B, Chen B, et al. MLLT3 Regulates Melanoma Stemness and Progression by Inhibiting HMGB1 Nuclear Entry and MAGEA1 M 5 C Modification. Advanced Science. 2025;12(10). doi:10.1002/advs.202408529
BibTeX
@article{Li2025,
author = {Li, Yaling and Liu, Hong and Li, Jingyi and Fu, Chang and Jiang, Bin and Chen, Bancheng and Zou, Yanfen and Yu, Bo and Song, Bing},
title = {MLLT3 Regulates Melanoma Stemness and Progression by Inhibiting HMGB1 Nuclear Entry and MAGEA1 M 5 C Modification},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {10},
doi = {10.1002/advs.202408529}
}
EUVIMED